|
|
|
SAN JOSE, Calif., Jan. 10 /PRNewswire - Laserscope, a pioneer in the development and commercialization of minimally-invasive medical devices, including medical lasers and advanced fiber-optic delivery devices, today announced the positive results of the first prospective study comparing Photoselective Vaporization of the Prostate (PVP) performed with the Company's GreenLight PV® laser system with the more traditional Transurethral Resection of the Prostate (TURP) for the treatment of obstructive Benign Prostatic Hyperplasia (BPH).
Investigators from the University of Basel and from Kantonsspital Baden in Switzerland reported their findings in the December issue of the European Urology journal.
The authors of the study, which included data from 101 patients, found that "PVP provides excellent intraoperative safety, instant tissue removal, and immediate relief from obstructive voiding symptoms, similar to TURP." Dr. Alexander Bachmann, the study's lead investigator, commented that, "PVP has become the standard of care at the University of Basel." Professor Tullio Sulser, Head of the Urology Department at the University of Basel, and senior author of the study added that, "The GreenLight PV® laser system has proven to be an extremely effective tool in our long-term experience of more then three years."
The authors also noted that PVP has the potential to reduce health care expenses for the treatment of obstructive BPH. "Although capital investment for the laser generator and disposable costs for the single-use laser fiber are significant, cost savings for insurers become evident once the shorter hospital stay, lower incidence and reduced severity of post-operative complications for PVP compared to TURP are taken into consideration."
"We are very excited to see published evidence of the significant advantages our GreenLight PV® laser system offers over TURP, which has been the 'Gold Standard' for the treatment of BPH over the last several decades," said Eric Reuter, President and Chief Executive Officer of Laserscope. "Although long-term, follow-up of comparison trials are still needed to confirm the initial positive results of this study, we are convinced that PVP is becoming the new de-facto standard of care given the growing number of consistently positive reports from educational and medical centers around the world."
Fulltext on demand / Volltext auf Verlangen
|